127 related articles for article (PubMed ID: 12879463)
1. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
2. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.
Okroj M; Holmquist E; Nilsson E; Anagnostaki L; Jirström K; Blom AM
Cancer Immunol Immunother; 2015 Apr; 64(4):467-78. PubMed ID: 25618258
[TBL] [Abstract][Full Text] [Related]
3. Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma
Conklin MW; Gangnon RE; Sprague BL; Van Gemert L; Hampton JM; Eliceiri KW; Bredfeldt JS; Liu Y; Surachaicharn N; Newcomb PA; Friedl A; Keely PJ; Trentham-Dietz A
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):138-145. PubMed ID: 29141852
[No Abstract] [Full Text] [Related]
4. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1-Induced ECM Fiber Alignment Requires Integrin αvβ3 and Syndecan-1 Ectodomain and Heparan Sulfate Chains.
Yang N; Friedl A
PLoS One; 2016; 11(2):e0150132. PubMed ID: 26909794
[TBL] [Abstract][Full Text] [Related]
6. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
Szarvas T; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky I; Rübben H
Hum Pathol; 2014 Apr; 45(4):674-82. PubMed ID: 24656090
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma.
Lendorf ME; Manon-Jensen T; Kronqvist P; Multhaupt HA; Couchman JR
J Histochem Cytochem; 2011 Jun; 59(6):615-29. PubMed ID: 21430259
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility.
Yang N; Mosher R; Seo S; Beebe D; Friedl A
Am J Pathol; 2011 Jan; 178(1):325-35. PubMed ID: 21224069
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.
Kind S; Merenkow C; Büscheck F; Möller K; Dum D; Chirico V; Luebke AM; Höflmayer D; Hinsch A; Jacobsen F; Göbel C; Weidemann S; Fraune C; Möller-Koop C; Hube-Magg C; Clauditz TS; Simon R; Sauter G; Wilczak W; Bawahab AA; Izbicki JR; Perez D; Marx A
Dis Markers; 2019; 2019():4928315. PubMed ID: 31976021
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
12. State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez B; Rivas-Pardo B; Gómez Del Moral M; Subiza JL; Martínez-Naves E
Cells; 2024 Apr; 13(9):. PubMed ID: 38727261
[TBL] [Abstract][Full Text] [Related]
13. Cell Membrane-Derived Nanovehicles for Targeted Therapy of Ischemic Stroke: From Construction to Application.
Hao C; Sha M; Ye Y; Wang C
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38276484
[TBL] [Abstract][Full Text] [Related]
14. Novel Implication of the Basement Membrane for Breast Cancer Outcome and Immune Infiltration.
Tian W; Luo Y; Tang Y; Kong Y; Wu L; Zheng S; Zou Y; Zhang C; Xie J; Deng X; Zhang J; Chen N; Xie X; Wei W
Int J Biol Sci; 2023; 19(5):1645-1663. PubMed ID: 37056938
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma.
Motta JM; Hassan H; Ibrahim SA
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980680
[TBL] [Abstract][Full Text] [Related]
16. Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells.
Hilgers K; Ibrahim SA; Kiesel L; Greve B; Espinoza-Sánchez NA; Götte M
Front Oncol; 2022; 12():803899. PubMed ID: 35155241
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women.
Rajkumar T; Amritha S; Sridevi V; Gopal G; Sabitha K; Shirley S; Swaminathan R
Sci Rep; 2022 Jan; 12(1):100. PubMed ID: 34997107
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells.
Valla S; Hassan N; Vitale DL; Madanes D; Spinelli FM; Teixeira FCOB; Greve B; Espinoza-Sánchez NA; Cristina C; Alaniz L; Götte M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070901
[TBL] [Abstract][Full Text] [Related]
19. The function role and synergic effect of syndecan-1 for mifepristone in uterine leiomyoma.
Shen X; Wang X
Cytotechnology; 2021 Apr; 73(2):179-187. PubMed ID: 33927475
[TBL] [Abstract][Full Text] [Related]
20. Syndecan-1 (CD138), Carcinomas and EMT.
Couchman JR
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
